Suppr超能文献

活化的肾巨噬细胞是狼疮性肾炎疾病发作和疾病缓解的标志物。

Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.

作者信息

Schiffer Lena, Bethunaickan Ramalingam, Ramanujam Meera, Huang Weiqing, Schiffer Mario, Tao Haiou, Madaio Michael P, Bottinger Erwin P, Davidson Anne

机构信息

Autoimmunity Center, Feinstein Institute for Medical Research, Manhasset, NY 11030, USA.

出版信息

J Immunol. 2008 Feb 1;180(3):1938-47. doi: 10.4049/jimmunol.180.3.1938.

Abstract

Costimulatory blockade with CTLA4Ig and anti-CD40L along with a single dose of cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F(1) mice. To understand the mechanisms for remission and for impending relapse, we examined the expression profiles of 61 inflammatory molecules in the perfused kidneys of treated mice and untreated mice at different stages of disease. Further studies using flow cytometry and immunohistochemistry allowed us to determine the cellular origins of several key markers. We show that only a limited set of inflammatory mediators is expressed in the kidney following glomerular immune complex deposition but before the onset of proteinuria. Formation of a lymphoid aggregate in the renal pelvis precedes the invasion of the kidney by inflammatory cells. Regulatory molecules are expressed early in the disease process and during remission but do not prevent the inevitable progression of active inflammation. Onset of proliferative glomerulonephritis and proteinuria is associated with activation of the renal endothelium, expression of chemokines that mediate glomerular cell infiltration, and infiltration by activated dendritic cells and macrophages that migrate to different topographical areas of the kidney but express a similar profile of inflammatory cytokines. Increasing interstitial infiltration by macrophages and progressive tubular damage, manifested by production of lipocalin-2, occur later in the disease process. Studies of treated mice identify a type II (M2b)-activated macrophage as a marker of remission induction and impending relapse and suggest that therapy for systemic lupus erythematosus nephritis should include strategies that prevent both activation of monocytes and their migration to the kidney.

摘要

用CTLA4Ig和抗CD40L进行共刺激阻断,同时给予单剂量环磷酰胺,可诱导NZB/W F(1)小鼠的系统性红斑狼疮性肾炎缓解。为了解缓解及即将复发的机制,我们检测了治疗小鼠和未治疗小鼠在疾病不同阶段灌注肾中61种炎症分子的表达谱。使用流式细胞术和免疫组织化学的进一步研究使我们能够确定几种关键标志物的细胞来源。我们发现,在肾小球免疫复合物沉积后但蛋白尿出现之前,肾脏中仅表达有限的一组炎症介质。肾盂中淋巴样聚集物的形成先于炎症细胞侵入肾脏。调节分子在疾病过程早期和缓解期表达,但不能阻止活动性炎症的不可避免进展。增殖性肾小球肾炎和蛋白尿的发生与肾内皮细胞活化、介导肾小球细胞浸润的趋化因子表达以及迁移至肾脏不同部位但表达相似炎症细胞因子谱的活化树突状细胞和巨噬细胞浸润有关。巨噬细胞间质浸润增加和以lipocalin-2产生为特征的进行性肾小管损伤在疾病过程后期出现。对治疗小鼠的研究确定II型(M2b)活化巨噬细胞是缓解诱导和即将复发的标志物,并表明系统性红斑狼疮性肾炎的治疗应包括预防单核细胞活化及其向肾脏迁移的策略。

相似文献

1
Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.
J Immunol. 2008 Feb 1;180(3):1938-47. doi: 10.4049/jimmunol.180.3.1938.
3
A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis.
J Immunol. 2011 Apr 15;186(8):4994-5003. doi: 10.4049/jimmunol.1003010. Epub 2011 Mar 16.
5
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Clin Immunol. 2018 Dec;197:205-218. doi: 10.1016/j.clim.2018.10.008. Epub 2018 Oct 16.
6
CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice.
J Immunol. 2014 Feb 1;192(3):886-96. doi: 10.4049/jimmunol.1300123. Epub 2013 Dec 23.
7
IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice.
J Immunol. 2011 Aug 1;187(3):1506-13. doi: 10.4049/jimmunol.1004142. Epub 2011 Jun 24.
8
Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis.
Front Immunol. 2024 Oct 1;15:1443153. doi: 10.3389/fimmu.2024.1443153. eCollection 2024.
9
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.
J Immunol. 2001 Mar 1;166(5):2913-6. doi: 10.4049/jimmunol.166.5.2913.

引用本文的文献

2
Infiltrating macrophages and interferon gamma rather than renal genotype dictate heightened crescentic glomerulonephritis.
Front Immunol. 2024 Dec 19;15:1484525. doi: 10.3389/fimmu.2024.1484525. eCollection 2024.
3
CXCL13: a common target for immune-mediated inflammatory diseases.
Clin Exp Med. 2024 Oct 24;24(1):244. doi: 10.1007/s10238-024-01508-8.
5
EGF-Receptor-Dependent TLR7 Signaling in Macrophages Promotes Glomerular Injury in Crescentic Glomerulonephritis.
Lab Invest. 2023 Sep;103(9):100190. doi: 10.1016/j.labinv.2023.100190. Epub 2023 Jun 1.
6
Pathogenic cellular and molecular mediators in lupus nephritis.
Nat Rev Nephrol. 2023 Aug;19(8):491-508. doi: 10.1038/s41581-023-00722-z. Epub 2023 May 24.
7
The Pathophysiological Role of Thymosin β4 in the Kidney Glomerulus.
Int J Mol Sci. 2023 Apr 22;24(9):7684. doi: 10.3390/ijms24097684.
9
Molecular mechanisms governing the progression of nephritis in lupus prone mice and human lupus patients.
Front Immunol. 2023 Mar 1;14:1147526. doi: 10.3389/fimmu.2023.1147526. eCollection 2023.
10
Macrophage: Key player in the pathogenesis of autoimmune diseases.
Front Immunol. 2023 Feb 14;14:1080310. doi: 10.3389/fimmu.2023.1080310. eCollection 2023.

本文引用的文献

1
PD-1 and its ligands in T-cell immunity.
Curr Opin Immunol. 2007 Jun;19(3):309-14. doi: 10.1016/j.coi.2007.04.012. Epub 2007 Apr 12.
2
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.
Nat Med. 2007 Apr;13(4):423-31. doi: 10.1038/nm1564. Epub 2007 Mar 25.
3
Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage.
Kidney Int. 2007 May;71(10):967-70. doi: 10.1038/sj.ki.5002165. Epub 2007 Mar 7.
4
Chemokines and chemokine receptors as therapeutic targets in lupus nephritis.
Semin Nephrol. 2007 Jan;27(1):81-97. doi: 10.1016/j.semnephrol.2006.09.010.
5
Autoimmune inflammation from the Th17 perspective.
Autoimmun Rev. 2007 Jan;6(3):169-75. doi: 10.1016/j.autrev.2006.10.002. Epub 2006 Nov 14.
6
Dual action of neutrophil gelatinase-associated lipocalin.
J Am Soc Nephrol. 2007 Feb;18(2):407-13. doi: 10.1681/ASN.2006080882. Epub 2007 Jan 17.
7
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Arthritis Rheum. 2007 Jan;56(1):274-9. doi: 10.1002/art.22327.
8
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.
J Exp Med. 2006 Nov 27;203(12):2737-47. doi: 10.1084/jem.20061577. Epub 2006 Nov 20.
9
Pathogenesis and treatment of systemic lupus erythematosus nephritis.
Curr Opin Rheumatol. 2006 Sep;18(5):468-75. doi: 10.1097/01.bor.0000240356.45550.13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验